RAVLT Delayed Recall predicts two‐year changes in cerebrospinal fluid total‐tau for cognitively healthy older adults

Our findings showcase that baseline RAVLT DR performance is a leading indicator of CSF t-tau change over two years in cognitively health older adults. Notably, baseline CSF t-tau level did not predict cognitive change over time. Given the RAVLT's low-cost and ease of administration, it has considerable promise for early prediction of subsequent AD-related fluid biomarker changes later in the disease course.